[1]王玲,樊芳,贾志旸.青光眼滤过性手术抗瘢痕化治疗的研究进展[J].眼科新进展,2020,40(11):1084-1089.[doi:10.13389/j.cnki.rao.2020.0242]
 WANG Ling,FAN Fang,JIA Zhiyang.Research progress of anti-scar treatment in glaucoma filtering surgery[J].Recent Advances in Ophthalmology,2020,40(11):1084-1089.[doi:10.13389/j.cnki.rao.2020.0242]
点击复制

青光眼滤过性手术抗瘢痕化治疗的研究进展/HTML
分享到:

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
40卷
期数:
2020年11期
页码:
1084-1089
栏目:
文献综述
出版日期:
2020-11-05

文章信息/Info

Title:
Research progress of anti-scar treatment in glaucoma filtering surgery
作者:
王玲樊芳贾志旸
050051 河北省石家庄市,河北省人民医院(王玲, 樊芳,贾志旸);063210 河北省唐山市,华北理工大学(王玲)
Author(s):
WANG Ling12FAN Fang1JIA Zhiyang1
1.Hebei General Hospital, Shijiazhuang 050051,Hebei Province,China
2.North China University of Science and Technology, Tangshan 063210,Hebei Province,China
关键词:
青光眼滤过性手术瘢痕化抗瘢痕治疗
Keywords:
glaucomafiltration surgeryfibrosisanti-scar therapy
分类号:
R775
DOI:
10.13389/j.cnki.rao.2020.0242
文献标志码:
A
摘要:
青光眼滤过性手术(glaucoma filtration surgery,GFS)作为抗青光眼的主要术式在临床上得到了广泛应用,但术后滤过泡的瘢痕化是导致手术失败的主要原因。术中及术后使用抗代谢药物如5-氟尿嘧啶(5-fluorouracil,5-FU)和丝裂霉素C(mitomycin-C,MMC)虽然有一定效果,但其具有威胁视力的严重并发症。为进一步提高GFS的成功率,抗瘢痕化治疗成为近年来的研究热点。本文对近年来青光眼滤过性手术的抗瘢痕化药物及新型材料的研究进行了综述,为临床中寻找抗瘢痕化效率高、不良反应少、安全性好的药物或材料提供了新的思路和方法。
Abstract:
Glaucoma filtration surgery (GFS) has been widely used in clinic as a major anti-glaucoma operation, but the scarring of the postoperative filtering bleb is the main reason for the failure of the operation. Intraoperative or postoperative use of antimetabolites such as 5-fluorouracil or mitomycin-c has been shown to be effective. However, it has serious complications that threaten vision. In order to improve the success rate of glaucoma filtration surgery, anti-scar therapy has become a research focus in recent years. This thesis reviews the research on anti-scar drugs and new materials for GFS in recent years, providing new ideas and methods for finding drugs or materials with high anti-scar efficiency, less side effects and good safety in clinic.

参考文献/References:

[1] THAM Y C,LI X,WONG T Y,QUIGLEY H A,AUNG T,CHENG C Y.Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis[J].Ophthalmology,2014,121(11):2081-2090.
[2] SHARPE R A,KAMMERDIENER L L,WILLIAMS D B,DAS S K,NUTAITIS M J.Efficacy of selective laser trabeculoplasty following incisional glaucoma surgery[J].Int J Ophthalmol,2018,11(1):71-76.
[3] WEINREB R N,AUNG T,MEDEIROS F A.The pathophysiology and treatment of glaucoma: a review[J].JAMA,2014,311(18):1901-1911.
[4] PAKRAVAN M,ESFANDIARI H,YAZDANI S,DOUZANDEH A,AMOUHASHEMI N,YASERI M,et al.Mitomycin C-augmented trabeculectomy: subtenon injection versus soaked sponges: a randomised clinical trial[J].Br J Ophthalmol,2017,101(9):1275-1280.
[5] KHAW P T,SHERWOOD M B,MACKAY S L,ROSSI M J,SCHULTZ G.Five-minute treatments with fluorouracil,floxuridine,and mitomycin have long-term effects on human Tenon’s capsule fibroblasts[J].Arch Ophthalmol,1992,110(8):1150-1154.
[6] JACOB J T,LACOUR O J,BURGOYNE C F.Slow release of the antimetabolite 5-fluorouracil (5-FU) from modified Baerveldt glaucoma drains to prolong drain function[J].Biomaterials,2001,22(24):3329-3335.
[7] CUI L J,SUN N X,LI X H,HUANG J,YANG J G.Subconjunctival sustained release 5-fluorouracil for glaucoma filtration surgery[J].Acta Pharmacol Sin,2008,29(9):1021-1028.
[8] 路振云.抗代谢药物预防青光眼术后滤过瘢痕的临床疗效观察[J].贵州医药,2019,43(4):580-582.
LU Z Y.Clinical efficacy of antimetabolic drugs in prevention of filtering scar after glaucoma surgery [J].Guizhou Med,2019,43(4):580-582.
[9] 崔现中,杨宇飞.抗代谢药物预防青光眼术后滤过瘢痕的临床疗效观察[J].临床研究,2019,27(12):289-296.
CUI X Z,YANG Y F.Clinical efficacy of antimetabolic drugs in prevention of filtering scar after glaucoma surgery[J].Clin Res,2019,27(12):289-296.
[10] RATNER M.Landmark approvals in idiopathic pulmonary fibrosis[J].Nat Biotechnol,2014,32(11):1069-1070.
[11] HEWITSON T D,KELYNACK K J,TAIT M G,MARTIC M,JONES C L,MARGOLIN S B,et al.Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis[J].J Nephrol,2001,14(6):453-460.
[12] TANIGUCHI H,EBINA M,KONDOH Y,OGURA T,AZUMA A,SUGA M,et al.Pirfenidone in idiopathic pulmonary fibrosis[J].Eur Respir J,2010,35(4):821-829.
[13] Di SARIO A,BENDIA E,SVEGLIATI BARONI G,RIDOLFI F,CASINI A,CENI E,et al.Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production[J].J Hepatol,2002,37(5):584-591.
[14] STAHNKE T,KOWTHARAPU B S,STACHS O,SCHMITZ K P,WURM J,WREE A,et al.Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro[J].PLoS One,2017,12(2):e172592.
[15] LIU X,YANG Y,GUO X,LIU L,WU K,YU M.The antiangiogenesis effect of pirfenidone in wound healing in vitro[J].J Ocul Pharmacol Ther,2017,33(9):693-703.
[16] ZHONG H,SUN G,LIN X,WU K,YU M.Evaluation of pirfenidone as a new postoperative antiscarring agent in experimental glaucoma surgery[J].Invest Ophthalmol Vis Sci,2011,52(6):3136-3142.
[17] WESTERMEYER H D,SALMON B,BAYNES R,YEATTS J,KHATTAB A,OH A,et al.Safety and efficacy of topically applied 0.5% and 1% pirfenidone in a canine model of subconjunctival fibrosis[J].Vet Ophthalmol,2019,22(4):502-509.
[18] PARK J H,YOO C,KIM Y Y.Effect of lovastatin on wound-healing modulation after glaucoma filtration surgery in a rabbit model[J].Invest Ophthalmol Vis Sci,2016,57(4):1871-1877.
[19] KIM M L,SUNG K R,SHIN J A,YOUNG YOON J,JANG J.Statins reduce TGF-beta2-modulation of the extracellular matrix in cultured astrocytes of the human optic nerve head[J].Exp Eye Res,2017,164:55-63.
[20] 康欣,申颖,赵海霞,王召格,关文英,葛瑞春,等.雷帕霉素在兔眼滤过性手术中的抗瘢痕作用[J].南方医科大学学报,2018,38(11):1389-1394.
KANG X,SHEN Y,ZHAO H X,WANG Z G,GUAN W Y,GE R C,et al.Anti-scarring effect of rapamycin in rabbits following glaucoma filtering surgery[J].J South Med Univ,2018,38(11):1389-1394.
[21] CINIK R,YKSEL N,PIRHAN D,ASLAN M,SUBA C,KARA Z E.The effect of everolimus on scar formation in glaucoma filtering surgery in a rabbit model[J].Curr Eye Res,2016,41(11):1438-1446.
[22] ZHANG F,LIU K,CAO M,QU J,ZHOU D,PAN Z,et al.Ro-siglitazone treatment prevents postoperative fibrosis in a rabbit model of glaucoma filtration surgery[J].Invest Ophthalmol Vis Sci,2019,60(7):2743-2752.
[23] YAMAMOTO K,KOKUBUN T,SATO K,AKAISHI T,SHIMAZAKI A,NAKAMURA M,et al.The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery[J].Sci Rep,2019,9(1):19288.
[24] RANGEL H,ROLIM H T,VIDIGAL P,ARAúJO I D,CRONEMBERGER S.Healing modulation in glaucoma surgery after application of subconjunctival triamcinolone acetate alone or combined with mitomycin C: an experimetal study[J].Rev Col Bras Cir,2018,45(4):e1861.
[25] HOGEWIND B F,PIJL B,HOYNG C B,THEELEN T.Purified triamcinolone acetonide as antifibrotic adjunct in glaucoma filtering surgery[J].Graefes Arch Clin Exp Ophthalmol,2013,251(4):1213-1218.
[26] KEOROCHANA N,KUNASUNTIWARAKUL S,TREESIT I,CHOONTANOM R.The efficacy of preoperative posterior subtenon injection of triamcinolone acetonide in noninfectious uveitic patients with secondary glaucoma undergoing trabeculectomy[J].Clin Ophthalmol,2017,11:2057-2063.
[27] ISOBE T,MIZUNO K,KANEKO Y,OHTA M,KOIDE T,TANABE S.Effects of K-115,a rho-kinase inhibitor,on aqueous humor dynamics in rabbits[J].Curr Eye Res,2014,39(8):813-822.
[28] KANEKO Y,OHTA M,INOUE T,MIZUNO K,ISOBE T,TANABE S,et al.Effects of K-115 (Ripasudil),a novel ROCK inhibitor,on trabecular meshwork and Schlemm’s canal endothelial cells[J].Sci Rep,2016,6:19640.
[29] TANIHARA H,INOUE T,YAMAMOTO T,KUWAYAMA Y,ABE H,ARAIE M,et al.Phase 2 randomized clinical study of a Rho kinase inhibitor,K-115,in primary open-angle glaucoma and ocular hypertension[J].Am J Ophthalmol,2013,156(4):731-736.
[30] GARNOCK-JONES K P.Ripasudil: first global approval[J].Drugs,2014,74(18):2211-2215.
[31] FUTAKUCHI A,INOUE T,FUJIMOTO T,INOUE-MOCHITA M,KAWAI M,TANIHARA H.The effects of ripasudil (K-115),a Rho kinase inhibitor,on activation of human conjunctival fibroblasts[J].Exp Eye Res,2016,149:107-115.
[32] AKAIWA K,NAMEKATA K,AZUCHI Y,SANO H,GUO X,KIMURA A,et al.Topical ripasudil suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma[J].Invest Ophthalmol Vis Sci,2018,59(5):2080-2089.
[33] KITAOKA Y,SASE K,TSUKAHARA C,KOJIMA K,SHIONO A,KOGO J,et al.Axonal protection by ripasudil,a Rho Kinase inhibitor,via modulating autophagy in TNF-induced optic nerve degeneration[J].Invest Ophthalmol Vis Sci,2017,58(12):5056-5064.
[34] SUH W,HAN K E,HAN J R.Safety of using matrix metalloproteinase inhibitor in experimental glaucoma filtration surgery[J].J Korean Med Sci,2017,32(4):666-671.
[35] WONG T T,MEAD A L,KHAW P T.Prolonged antiscarring effects of ilomastat and MMC after experimental glaucoma filtration surgery[J].Invest Ophthalmol Vis Sci,2005,46(6):2018-2022.
[36] MARTORANA G M,SCHAEFER J L,LEVINE M A,LUKOWSKI Z L,MIN J,MEYERS C A,et al.Sequential therapy with Saratin,Bevacizumab and Ilomastat to prolong bleb function following glaucoma filtration surgery in a rabbit model[J].PLoS One,2015,10(9):e138054.
[37] MOHAMED-AHMED A,LOCKWOOD A,FADDA H,MADAAN S,KHAW P T,BROCCHINI S,et al.LC-MS analysis to determine the biodistribution of a polymer coated ilomastat ocular implant[J].J Pharm Biomed Anal,2018,157:100-106.
[38] VAN BERGEN T,ZAHN G,CALDIROLA P,FSADNI M,CARAM-LELHAM N,VANDEWALLE E,et al.Integrin α5β1 inhibition by CLT-28643 reduces postoperative wound healing in a mouse model of glaucoma filtration surgery[J].Invest Ophthalmol Vis Sci,2016,57(14):6428-6439.
[39] SCHULTHEISS M,SCHNICHELS S,KONRAD E M,BARTZ-SCHMIDT K U,ZAHN G,CALDIROLA P,et al.α5β1-integrin inhibitor (CLT-28643) effective in rabbit trabeculectomy model[J].Acta Ophthalmol,2017,95(1):e1-e9.
[40] CARMELIET P,FERREIRA V,BREIER G,POLLEFEYT S,KIECKENS L,GERTSENSTEIN M,et al.Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele[J].Nature,1996,380(6573):435-439.
[41] KIM M,LEE C,PAYNE R,YUE B Y,CHANG J H,YING H.Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review[J].Surv Ophthalmol,2015,60(6):524-535.
[42] PARK H Y,KIM J H,PARK C K.VEGF induces TGF-β1 expression and myofibroblast transformation after glaucoma surgery[J].Am J Pathol,2013,182(6):2147-2154.
[43] MULCAHY M F,BENSON A B.Bevacizumab in the treatment of colorectal cancer[J].Expert Opin Biol Ther,2005,5(7):997-1005.
[44] LI Z,Van BERGEN T,VAN DE VEIRE S,VAN DE VEL I,MOREAU H,DEWERCHIN M,et al.Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery[J].Invest Ophthalmol Vis Sci,2009,50(11):5217-5225.
[45] MEMARZADEH F,VARMA R,LIN L T,PARIKH J G,DUSTIN L,ALCARAZ A,et al.Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit[J].Invest Ophthalmol Vis Sci,2009,50(7):3233-3237.
[46] KOBAT S G,CELIKER F U,DAGLI A F,KASAR K.The effect on wound healing of pazopanib and bevacizumab compared with corticosteroid in experimental glaucoma filtration surgery[J].Int J Ophthalmol,2018,11(12):1909-1915.
[47] CHENG G,XIANG H,YANG G,MA J,ZHAO J.Bevacizumab inhibits angiogenesis and inflammation in rat filtration surgery model[J].Cell Biochem Biophys,2015,73(1):71-77.
[48] ZUO L,ZHANG J,XU X.Combined application of Bevacizumab and Mitomycin C or Bevacizumab and 5-Fluorouracil in experimental glaucoma filtration surgery[J].J Ophthalmol,2018,2018:8965709.
[49] ZHANG Y,ZHU S,XU X,ZUO L.In vitro study of combined application of Bevacizumab and 5-Fluorouracil or Bevacizumab and Mitomycin C to inhibit scar formation in glaucoma filtration surgery[J].J Ophthalmol,2019,2019:7419571.
[50] MUHSEN S,COMPAN J,LAI T,KRANEMANN C,BIRT C.Postoperative adjunctive bevacizumab versus placebo in primary trabeculectomy surgery for glaucoma[J].Int J Ophthalmol,2019,12(10):1567-1574.
[51] IWASE T,OVESON B C,HASHIDA N,LIMA E SILVA R,SHEN J,KRAUSS A H,et al.Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit[J].Invest Ophthalmol Vis Sci,2013,54(1):503-511.
[52] TRAN J,CRAVEN C,WABNER K,SCHMIT J,MATTER B,KOMPELLA U,et al.A pharmacodynamic analysis of choroidal neovascularization in a porcine model using three targeted drugs[J].Invest Ophthalmol Vis Sci,2017,58(9):3732-3740.
[53] KHAN S B,COOK H T,BHANGAL G,SMITH J,TAM F W,PUSEY C D.Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis[J].Kidney Int,2005,67(5):1812-1820.
[54] Di SABATINO A,CICCOCIOPPO R,BENAZZATO L,STURNIOLO G C,CORAZZA G R.Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn’s disease patients[J].Aliment Pharmacol Ther,2004,19(9):1019-1024.
[55] TURGUT B,EREN K,AKIN M M,DEMIR T,KOBAT S.Topical infliximab for the suppression of wound healing following experimental glaucoma filtration surgery[J].Drug Des Devel Ther,2014,8:421-429.
[56] NIKITA E,MOULIN A,VERGADOS I,BROUZAS D,THEODOSSIADIS P G.A pilot study on ocular safety and efficacy of infliximab as an antifibrotic agent after experimental glaucoma filtration surgery[J].Ophthalmol Ther,2017,6(2):323-334.
[57] CHONG R S,LEE Y S,CHU S,TOH L Z,WONG T.Inhibition of monocyte chemoattractant protein 1 prevents conjunctival fibrosis in an experimental model of glaucoma filtration surgery[J].Invest Ophthalmol Vis Sci,2017,58(9):3432-3439.
[58] ELBASHIR S M,HARBORTH J,LENDECKEL W,YALCIN A,WEBER K,TUSCHL T.Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells[J].Nature,2001,411(6836):494-498.
[59] ESNAULT C,STEWART A,GUALDRINI F,EAST P,HORSWELL S,MATTHEWS N,et al.Rho-actin signaling to the MRTF coactivators dominates the immediate transcriptional response to serum in fibroblasts[J].Genes Dev,2014,28(9):943-958.
[60] OLSON E N,NORDHEIM A.Linking actin dynamics and gene transcription to drive cellular motile functions[J].Nat Rev Mol Cell Biol,2010,11(5):353-365.
[61] FERNANDO O,TAGALAKIS A D,AWWAD S,BROCCHINI S,KHAW P T,HART S L,et al.Development of targeted siRNA nanocomplexes to prevent fibrosis in experimental glaucoma filtration surgery[J].Mol Ther,2018,26(12):2812-2822.
[62] YAO H W,LI J.Epigenetic modifications in fibrotic diseases: implications for pathogenesis and pharmacological targets[J].J Pharmacol Exp Ther,2015,352(1):2-13.
[63] PANG M,KOTHAPALLY J,MAO H,TOLBERT E,PONNUSAMY M,CHIN Y E,et al.Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy[J].Am J Physiol Renal Physiol,2009,297(4):F996-F1005.
[64] WANG Z,CHEN C,FINGER S N,KWAJAH S,JUNG M,SCHWARZ H,et al.Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis?[J].Eur Respir J,2009,34(1):145-155.
[65] KEE H J,SOHN I S,NAM K I,PARK J E,QIAN Y R,YIN Z,et al.Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin Ⅱ infusion and aortic banding[J].Circulation,2006,113(1):51-59.
[66] ROMBOUTS K,NIKI T,GREENWEL P,VANDERMONDE A,WIELANT A,HELLEMANS K,et al.Trichostatin A,a histone deacetylase inhibitor,suppresses collagen synthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts[J].Exp Cell Res,2002,278(2):184-197.
[67] SHARMA A,MEHAN M M,SINHA S,COWDEN J W,MOHAN R R.Trichostatin a inhibits corneal haze in vitro and in vivo[J].Invest Ophthalmol Vis Sci,2009,50(6):2695-2701.
[68] NIKI T,ROMBOUTS K,De BLESER P,De SMET K,ROGIERS V,SCHUPPAN D,et al.A histone deacetylase inhibitor,trichostatin A,suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture[J].Hepatology,1999,29(3):858-867.
[69] XU W S,PARMIGIANI R B,MARKS P A.Histone deacetylase inhibitors: molecular mechanisms of action[J].Oncogene,2007,26(37):5541-5552.
[70] SHARMA A,ANUMANTHAN G,REYES M,CHEN H,BRUBAKER J W,SIDDIQUI S,et al.Epigenetic modification prevents excessive wound healing and scar formation after glaucoma filtration surgery[J].Invest Ophthalmol Vis Sci,2016,57(7):3381-3389.
[71] RODGERS C D,LUKOWSKI Z L,MIN J,MARTORANA G M,WILSON M K,SCHAEFER J L,et al.Modulating ocular scarring in glaucoma filtration surgery using the epigenetic adjunct suberoylanilide hydroxamic acid[J].J Curr Glaucoma Pract,2019,13(1):37-41.
[72] SEET L F,TOH L Z,FINGER S N,CHU S W,STEFANOVIC B,WONG T T.Valproic acid suppresses collagen by selective regulation of Smads in conjunctival fibrosis[J].J Mol Med (Berl),2016,94(3):321-334.
[73] SEET L F,TOH L Z,FINGER S N,CHU S,WONG T T.Valproic acid exerts specific cellular and molecular anti-inflammatory effects in post-operative conjunctiva[J].J Mol Med (Berl),2019,97(1):63-75.
[74] WONG K K,CHEUNG S O,HUANG L,NIU J,TAO C,HO C M,et al.Further evidence of the anti-inflammatory effects of silver nanoparticles[J].ChemMedChem,2009,4(7):1129-1135.
[75] LIU X,LEE P Y,HO C M,LUI V C,CHEN Y,CHE C M,et al.Silver nanoparticles mediate differential responses in keratinocytes and fibroblasts during skin wound healing[J].Chem Med Chem,2010,5(3):468-475.
[76] BUTLER M R,PROSPERO PONCE C M,WEINSTOCK Y E,ORENGO-NANIA S,CHEVEZ-BARRIOS P,FRANKFORT B J.Topical silver nanoparticles result in improved bleb function by increasing filtration and reducing fibrosis in a rabbit model of filtration surgery[J].Invest Ophthalmol Vis Sci,2013,54(7):4982-4990.
[77] HE M,HAN B,JIANG Z,YANG Y,PENG Y,LIU W.Synthesis of a chitosan-based photo-sensitive hydrogel and its biocompatibility and biodegradability[J].Carbohydr Polym,2017,166:228-235.
[78] QIAO X,PENG X,QIAO J,JIANG Z,HAN B,YANG C,et al.Evaluation of a photocrosslinkable hydroxyethyl chitosan hydrogel as a potential drug release system for glaucoma surgery[J].J Mater Sci Mater Med,2017,28(10):149.
[79] FILI S,SEDDIG S,KOHLHAAS M.Long-term results after trabeculectomy combined with mitomycin C and ologen implant[J].Klin Monbl Augenheilkd,2019,236(9):1107-1114.
[80] 张劲,朱剑.加味桑白皮汤对青光眼滤过术后滤过泡 瘢痕形成的影响研究[J].现代中西医结合杂志,2019,28(12):1307-1310.
ZHANG J,ZHU J.Effect of modified mulberry white skin decoction on the formation of filtration bubble scar after glaucoma filtration surgery[J].Mod J Int Trad Chin West Med,2019,28(12):1307-1310.
[81] YU J,QIU L X,QING G P,ZHAO B W,WANG H.Modified Cortex Mori Capsules improving the successful rate of functional filtering blebs after reclinical glaucoma filtering surgery[J].World J Clin Cases,2019,7(21):3436-3445.
[82] 李苑碧,彭清华,黄学思,陈晓柳,谭涵宇.青光安对抗青光眼术后滤过道瘢痕组织中弹性纤维、MMP-7、TlMP-1的实验研究[J].国际眼科杂志,2015,15(1):20-25.
LI Y B, PENG Q H, HUANG X S,CHEN X L,TAN H Y.Effect of Qingguang’an on elastic fiber,MMP- 7,TlMP - 1 in scarring area of filtration canal after glaucoma surgery[J].Int Eye Sci,2015,15(1):20-25.
[83] 喻娟,彭清华.青光安颗粒剂对TGF-β1诱导的HTFs增殖影响的实验研究[J].中华细胞与干细胞杂志(电子版),2019,9(2):79-85.
YU J,PENG Q H.Effect of Qingguang’an granule on the proliferation of HTFs induced by TGF-beta 1[J].Chin J Cell Stem Cell,2019,9(2):79-85.
[84] 喻娟,彭俊,颜家朝.青光安颗粒对青光眼滤过术后滤过泡瘢痕化的抑制作用[J].世界中医药,2019,14(3):679-681,686.
YU J,PENG J,YAN J C.Inhibitory effects of Qingguang’an granule on filtering bleb scar after glaucoma filtration[J].World Chin Med,2019,14(3):679-681,686.

相似文献/References:

[1]李翔 谢钊 郭红建 谢学军 路雪婧 王毅 王超.补肾活血中药对大鼠慢性高眼压模型外侧膝状体病理改变的影响[J].眼科新进展,2012,32(1):000.
[2]范虹 刘五存 蔡鸿英 赵堪兴.改良二极管激光睫状体光凝术治疗中晚期青光眼[J].眼科新进展,2012,32(4):000.
[3]王建萍 赵燕麟 马勇 朱涛 程燕 车选义 赵桂娥 王柯.噻吗洛尔和布林佐胺联合曲伏前列素治疗原发性开角型青光眼与高眼压患者的临床研究[J].眼科新进展,2012,32(5):000.
[4]彭坤 靳隽 杨玉新 许银霞 王保君 闫义涛 杨华.长期联合应用噻吗洛尔对结膜组织炎性标记物ICAM-1和HLA-DR表达的影响[J].眼科新进展,2012,32(6):000.
[5]马恩普 赵小钊 董良 刘苏冰 曾照年.Healaflow在青光眼小梁切除术中的应用[J].眼科新进展,2012,32(6):000.
[6]王勇 叶应嘉 鲍先议 周龑丽 许荣 彭婷婷 曾志富.同轴微小切口超声乳化吸出术在青光眼滤过术后白内障摘出术中的应用[J].眼科新进展,2012,32(7):000.
[7]李翔 马世勇 李娟 王毅.补肾活血中药对大鼠慢性高眼压模型视神经病理改变的影响[J].眼科新进展,2013,33(2):000.
[8]白东娥 刘伟 季建.抗青光眼药物对青光眼患者泪液胰岛素水平的影响及其与眼表改变的关系[J].眼科新进展,2013,33(6):000.
[9]马英慧 张铁民 齐建平.原发性开角型青光眼与慢性原发性闭角型青光眼视网膜神经纤维层厚度与视野缺损的关系[J].眼科新进展,2013,33(7):000.
[10]张海涛 杨玉新 毛永 丁晓丽 秦海霞 梁长华 郭英昌.青光眼与非炎症性缺血型视神经病变的傅立叶OCT扫描视神经形态学对比[J].眼科新进展,2013,33(8):000.

备注/Memo

备注/Memo:
国家自然科学基金资助(编号:81700835)
更新日期/Last Update: 2020-11-05